Given the current inefficiency in DCM therapy, targeting P2X7R and NLRP3 inflammasome or/and the related pyroptosis might be an effective alternative therapeutic strategy for chronic cardiomyopathy and heart failure. The gene discussed is NLRP3; the disease is familial dilated cardiomyopathy.